Trials / Unknown
UnknownNCT04470141
A Study of SHC014748M in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma
A Phase II, Multicenter Study to Investigate the Efficacy and Safety of SHC014748M in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 130 (estimated)
- Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of SHC014748M in patients with relapsed or refractory relapsed or refractory Peripheral T Cell Lymphoma.
Detailed description
This is a phase II, multicenter study to assess the efficacy and safety of SHC014748M, an oral inhibitor of PI3K delta, in patients with relapsed or refractory peripheral T cell lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHC014748M treatment | Each treatment cycle is comprised of 28-day consecutive dosing of SHC014748M, 200mg QD (Days 1 to28). Upon completion of each cycle, patients may continue to receive oral SHC014748M if they can benefit from the treatment and the toxicity is tolerable. |
Timeline
- Start date
- 2020-08-01
- Primary completion
- 2021-05-01
- Completion
- 2021-07-01
- First posted
- 2020-07-14
- Last updated
- 2020-07-14
Source: ClinicalTrials.gov record NCT04470141. Inclusion in this directory is not an endorsement.